BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41st Annual Health Care Conference. Presentation details can be found below. Day: Tuesday, March 2, 2021 Time: 2:10pm Eastern Time Format: Fireside chat Webcast Link: https://wsw.com/webcast/cowen81/vyne/1982826 About VYNE Therapeutics Inc.VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond. With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of…

Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical development plans, will be discussed on VYNE’s year end 2020 earnings call at 8:30am ET March 4 BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced development plans for FMX114, a fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for the potential treatment of mild-to-moderate atopic dermatitis (AD). FMX114, VYNE’s first product…

Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical development plans, will be discussed on VYNE’s year end 2020 earnings call at 8:30am ET March 4 BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced development plans for FMX114, a fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for the potential treatment of mild-to-moderate atopic dermatitis (AD). FMX114, VYNE’s first product…

BRIDGEWATER, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, March 4, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Join the Webcast

BRIDGEWATER, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, March 4, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Thursday, March 4th @ 8:30am Eastern Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13715616 Live Event Call me™ Click Here:   • Participants can use Guest dial-in #s above and be answered…

BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of the Company’s common stock at a ratio of 1-for-4. The reverse stock split was previously approved by stockholders at the Annual Meeting of Stockholders held on August 3, 2020. VYNE’s common stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market at the market open on February 16, 2021. Once effective, the reverse stock split will reduce the number of shares of common stock issued and…